Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer?
نویسندگان
چکیده
Activated Clotting Time During Percutaneous Coronary Intervention: A Test for All Seasons or a Mind Tranquilizer? Gjin Ndrepepa, MD; Adnan Kastrati, MD · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · e002576 Transcatheter Aortic Valve Replacement Failure: Déjà vu ou Jamais vu? Darren Mylotte, MB BCh, MD; Nicolo Piazza, MD, PhD · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · e002531 Effect of Right Ventricular Function and Tricuspid Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation: Forgotten Side of the Heart Fabien Praz, MD; Stephan Windecker, MD · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · e002577
منابع مشابه
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
BACKGROUND Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for >20 years. Despite the availability of rapid "point of care" testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the absence of large-scale, well-conducted...
متن کاملActivated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial.
BACKGROUND Activated clotting time (ACT) is widely used to guide unfractionated heparin dosing during percutaneous coronary intervention. However, its value in predicting complications is controversial in the modern era. We sought to examine the relationship between ACT and outcomes in non-ST-segment-elevation acute coronary syndrome patients. METHODS AND RESULTS In the Fondaparinux With Unfr...
متن کاملEffect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide.
Three hundred nine patients were followed during their recovery area stay after percutaneous coronary intervention. Recovery area times for patients who received bivalirudin during percutaneous coronary intervention showed an average reduction in total recovery area length of stay of 36 minutes (p <0.0001) compared with patients who received heparin alone. This reduction was also seen when comp...
متن کاملEvaluation of bivalirudin hyper- and hypo-ACT responses in the setting of percutaneous coronary intervention.
BACKGROUND Bivalirudin has emerged as a suitable alternative anticoagulant to unfractionated heparin and low-molecular-weight heparins during percutaneous coronary intervention (PCI) procedures in the management of coronary artery disease and acute coronary syndromes (ACS). In clinical trials, bivalirudin dosing was standardized, and activated clotting time (ACT) did not influence dosing adjust...
متن کاملActivated Clotting Time Level with Weight Based Heparin Dosing During Percutaneous Coronary Intervention and its Determinant Factors
INTRODUCTION Percutaneous coronary intervention (PCI) may be associated with Thrombotic complications. Unfractionated heparin (UFH) is a potent and preferable antithrombotic agent during this procedure. Activated clotting time (ACT) is a good assay for accurate titration of UFH during PCI. The aim of this study was to evaluate ACT levels 10 minutes after administration of 100U/kg IV heparin and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation. Cardiovascular interventions
دوره 8 4 شماره
صفحات -
تاریخ انتشار 2015